SM
PGNX

Sabby Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Sabby Management’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-130
Closed -$55K – 358
2016
Q2 		$55K Hold
130
– – ﹤0.01% 270
2016
Q1 		$57K Buy
+130
New +$579 ﹤0.01% 278
2015
Q3 		– Sell
-3,369
Closed -$2.51M – 419
2015
Q2 		$2.51M Buy
3,369
+10
+0.3% +$61 0.09% 146
2015
Q1 		$2.01M Buy
+3,359
New +$21.1K 0.08% 146
2014
Q3 		– Sell
-117
Closed -$50K – 317
2014
Q2 		$50K Sell
117
-181
-61% -$691 ﹤0.01% 244
2014
Q1 		$122K Hold
298
– – 0.01% 218
2013
Q4 		$159K Buy
+298
New +$1.31K 0.01% 189

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Sabby Management's PGNX Position: Q3 2016 in Review

Sabby Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q3 2016, closing a stake of 174,900 shares — an estimated $738K sold.

Sabby Management first reported a position in PGNX in Q1 2014 and held it in 7 quarters. The position peaked at $3.7M in Q1 2015. 115 funds tracked by Wall St. Rank hold PGNX as of Q3 2016.

  • Sabby Management reported no remaining Progenics Pharmaceuticals Inc position as of Q3 2016 after selling out during the quarter.
  • Sabby Management sold 174,900 Progenics Pharmaceuticals Inc shares in Q3 2016, an estimated $738K.
  • Sabby Management first reported a position in Progenics Pharmaceuticals Inc in Q1 2014 and held it in 7 quarters.
  • Sabby Management's Progenics Pharmaceuticals Inc position peaked at $3.7M in Q1 2015.
  • 115 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q3 2016.

Based on Sabby Management's 13F filing for Q3 2016, filed 14 Nov 2016.